Ptc Therapeutics Inc (PTCT) 53.37 $PTCT
PTC Therapeutics awards inducement grants to 13 new employees as part of Nasdaq Listing Rule 5635(c)(4)
M2 - Mon Feb 09, 5:48AM CST
Drug company PTC Therapeutics (NasdaqGS
TCT) on Friday declared non-statutory stock options to purchase an aggregate of 66,750 shares of its common stock to 13 new employees.
PTCT: 53.37 (-0.74)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire - Fri Feb 06, 4:00PM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on February 6, 2015 it approved non-statutory stock options to purchase an aggregate of 66,750 shares of its common stock to 13 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our new hires' employment compensation.
PTCT: 53.37 (-0.74)
PTC Therapeutics to Participate at Upcoming Investor Conferences
PR Newswire - Thu Feb 05, 3:30PM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences:
PTCT: 53.37 (-0.74)
Convert Catalysts Into Profits: Sagient Research's Edward Stopke
Life Sciences Report - Seeking Alpha - Fri Jan 23, 7:51AM CST
The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. But realistically assessing the therapeutic potential of pipeline products is the healthy approach for selecting a winner. In this interview...
CPXX: 3.10 (+0.07), RPTP: 9.05 (-0.40), SRPT: 12.76 (+0.11), CLDX: 20.97 (+0.53), PTCT: 53.37 (-0.74), RMTI: 11.17 (+0.15), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
Marathon Pharma DMD drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Mon Jan 19, 4:38PM CST
ROSG: 3.65 (+0.32), RNA: 18.65 (unch), PFE: 34.64 (-0.23), SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74)
Cramer's Mad Money: Cramer's Game Plan (1/16/15)
SA Editor Michael Hopkins - at Seeking Alpha - Sun Jan 18, 12:06AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, January 16. After a few big drubbings, stocks caught a break Friday, thanks to a rally in oil and a strong consumer confidence number, data Cramer said is...
GD: 137.61 (-0.54), GE: 25.15 (+0.26), BOX: 20.18 (+0.01), NKE: 92.04 (+0.04), HON: 104.38 (+0.88), DAL: 44.50 (-0.31), RLYP: 33.98 (+0.60), UNH: 109.44 (-0.40), HAL: 44.19 (+1.42), BAC: 16.61 (-0.06), EEP: 38.84 (-0.50), SLB: 88.38 (+2.42), PEP: 99.13 (-1.14), NFLX: 466.10 (+9.37), SBUX: 91.58 (-0.24), UA: 73.76 (-0.19), PBR: 6.98 (+0.44), WBA: 78.73 (-1.23), IBM: 160.40 (+1.88), STI: 41.57 (+0.01), PTCT: 53.37 (-0.74), LEN.B: 40.12 (-0.13), VZ: 49.31 (-0.21), UNP: 122.60 (-1.23), URI: 92.98 (+1.41)
Jim Cramer's Top Stock Picks: GD PTCT RLYP HON PEP
at The Street - Sat Jan 17, 5:00AM CST
Cramer says he'd buy General Dynamics ahead of earnings and he's a big fan of Honeywell and Pepsico.
GD: 137.61 (-0.54), HON: 104.38 (+0.88), RLYP: 33.98 (+0.60), PTCT: 53.37 (-0.74), PEP: 99.13 (-1.14)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Jan 16, 7:33PM CST
Cramer will be watching Europe plue earnings from Halliburton, Starbucks and Verizon, among many others.
GD: 137.61 (-0.54), ZIOP: 9.64 (-0.35), AVP: 9.08 (+0.39), HON: 104.38 (+0.88), UNH: 109.44 (-0.40), RLYP: 33.98 (+0.60), DECK: 77.08 (+0.61), HAL: 44.19 (+1.42), CVRR: 20.20 (+0.58), DENN: 10.68 (+0.03), PEP: 99.13 (-1.14), SBUX: 91.58 (-0.24), NFLX: 466.10 (+9.37), IBN: 11.70 (+0.06), IBM: 160.40 (+1.88), PTCT: 53.37 (-0.74), VZ: 49.31 (-0.21), UNP: 122.60 (-1.23), URI: 92.98 (+1.41)
Sarepta Is Suffering From Overreaction
Value Insight - at Seeking Alpha - Thu Jan 15, 8:00AM CST
SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74)
PTC Therapeutics to Present at the 33rd Annual J.P. Morgan Healthcare Conference
PR Newswire - Wed Jan 07, 7:00AM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the 33rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15th at 11:00 am PT at the Westin St. Francis in San Francisco.
JPM: 59.67 (+0.10), PTCT: 53.37 (-0.74)
Jim Cramer's 'Mad Money' Recap: Knowing Where to Look for Bargains
at The Street - Tue Jan 06, 7:25PM CST
The markets are presenting a buying opportunity at current levels, but only if you know which stocks to buy, Cramer says.
TSLA: 203.77 (+0.89), GE: 25.15 (+0.26), OVAS: 44.32 (+0.87), NMM: 12.37 (+0.24), XOM: 93.37 (+1.00), T: 34.66 (+0.05), ESPR: 67.13 (-0.33), IBM: 160.40 (+1.88), IRE: 14.54 (+0.81), DTV: 87.51 (-0.32), PTCT: 53.37 (-0.74), RCPT: 115.83 (-0.66), TEG: 75.56 (-1.61), PPG: 236.77 (+3.74), WAG: 76.05 (-0.49), BLUE: 90.70 (+0.93), TGTX: 13.13 (-0.19), WFC: 55.33 (+0.47), BA: 149.73 (+1.64), RAD: 8.34 (+0.25), ISIS: 63.86 (-0.43), RNA: 18.65 (unch), ACHN: 10.89 (-0.20), JCP: 8.05 (+0.14), CVS: 102.63 (-0.37), MCD: 95.65 (+0.56), AGIO: 118.55 (+0.11), CVX: 112.78 (+1.92), VZ: 49.31 (-0.21), FOLD: 8.36 (-0.11)
PTC Therapeutics awards inducement grants to 11 new employees under NASDAQ Listing Rule 5635(c)(4)
M2 - Mon Jan 05, 6:05AM CST
Biopharmaceutical company PTC Therapeutics (NasdaqGS TCT) on Friday authorised non-statutory stock options to purchase an aggregate of 26,600 shares of its common stock to 11 new employees in accordance with NASDAQ Listing Rule 5635(c)(4).
PTCT: 53.37 (-0.74)
The Market's Top 10 Stocks of 2014
Dan Caplinger, The Motley Fool - Motley Fool - Sat Jan 03, 8:00AM CST
For six years now, investors have looked with skepticism at the rise in the stock market. And for a sixth straight year, the markets defied those who were waiting for a major downturn to invest, with the S&P 500 climbing about 14% including...
BLUE: 90.70 (+0.93), TTPH: 35.18 (-0.73), AVNR: 16.96 (unch), SWKS: 81.85 (-0.57), CMRX: 40.16 (+0.08), ACHN: 10.89 (-0.20), HA: 18.72 (-0.31), RCPT: 115.83 (-0.66), PTCT: 53.37 (-0.74), AGIO: 118.55 (+0.11)
PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire - Fri Jan 02, 4:15PM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 2, 2015 it approved non-statutory stock options to purchase an aggregate of 26,600 shares of its common stock to 11 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our new hires' employment compensation.
PTCT: 53.37 (-0.74)
The Zacks Analyst Blog Highlights: Tekmira, Chimerix, Gilead, AbbVie, Achillion Pharmaceuticals, Agios Pharmaceuticals, PTC Therapeutics and Tetraphase Pharmaceuticals
PR Newswire - Mon Dec 29, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Tekmira (Nasdaq:TKMR-Free Report), Chimerix (Nasdaq:CMRX-Free Report), Gilead (Nasdaq:GILD-Free Report), AbbVie (NYSE:ABBV-Free Report), Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN-Free Report), Agios Pharmaceuticals, Inc. (Nasdaq:AGIO-Free Report), PTC Therapeutics, Inc. (Nasdaq TCT-Free Report) and Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH-Free Report).
ACHN: 10.89 (-0.20), PTCT: 53.37 (-0.74), AGIO: 118.55 (+0.11)
PTC Therapeutics Starts Rolling NDA Filing for Translarna - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:10PM CST
PTC Therapeutics (PTCT) initiated the process of a rolling submission of a new drug application to the FDA for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy.
RNA: 18.65 (unch), SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74), BIOD: 1.38 (-0.14)
PTC Therapeutics begins rolling submission of Translarna's NDA to the US FDA for treating nonsense mutation Duchenne muscular dystrophy
M2 - Wed Dec 24, 3:46AM CST
Biopharmaceutical company PTC Therapeutics (NasdaqGS TCT) reported on Tuesday the initiation of a rolling submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).
PTCT: 53.37 (-0.74)
BioMarin CEO Sees Big Future For Prosensa Drug
at Investor's Business Daily - Tue Dec 23, 3:11PM CST
BioMarin Pharmaceuticals raised a few eyebrows last month when it announced its latest buyout. BioMarin (BMRN) agreed to pay $680 million upfront for Prosensa Holding (RNA), a Dutch biotech developing a drug for Duchenne muscular dystrophy called...
BMRN: 100.76 (+1.98), RNA: 18.65 (unch), PTCT: 53.37 (-0.74), GSK: 47.94 (+1.99)
PTC Therapeutics begins rolling NDA for DMD
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:20AM CST
ROSG: 3.65 (+0.32), RNA: 18.65 (unch), SRPT: 12.76 (+0.11), PFE: 34.64 (-0.23), PTCT: 53.37 (-0.74)
PTC Therapeutics Begins Rolling NDA Submission to the FDA for Translarna to Treat Duchenne Muscular Dystrophy
PR Newswire - Tue Dec 23, 7:00AM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has commenced a rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for Translarna(TM) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). A rolling submission allows completed portions of the application to be submitted and reviewed by the FDA on an ongoing basis. PTC expects to finalize the application in the fourth quarter of 2015 following the completion of the ACT DMD confirmatory Phase 3 clinical trial.
PTCT: 53.37 (-0.74)
PTC Therapeutics awards inducement grants to 13 new employees as part of Nasdaq Listing Rule 5635(c)(4)
M2 - Mon Feb 09, 5:48AM CST
Drug company PTC Therapeutics (NasdaqGS
TCT) on Friday declared non-statutory stock options to purchase an aggregate of 66,750 shares of its common stock to 13 new employees. PTCT: 53.37 (-0.74)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire - Fri Feb 06, 4:00PM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on February 6, 2015 it approved non-statutory stock options to purchase an aggregate of 66,750 shares of its common stock to 13 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our new hires' employment compensation.
PTCT: 53.37 (-0.74)
PTC Therapeutics to Participate at Upcoming Investor Conferences
PR Newswire - Thu Feb 05, 3:30PM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences:
PTCT: 53.37 (-0.74)
Convert Catalysts Into Profits: Sagient Research's Edward Stopke
Life Sciences Report - Seeking Alpha - Fri Jan 23, 7:51AM CST
The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. But realistically assessing the therapeutic potential of pipeline products is the healthy approach for selecting a winner. In this interview...
CPXX: 3.10 (+0.07), RPTP: 9.05 (-0.40), SRPT: 12.76 (+0.11), CLDX: 20.97 (+0.53), PTCT: 53.37 (-0.74), RMTI: 11.17 (+0.15), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)
Marathon Pharma DMD drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Mon Jan 19, 4:38PM CST
ROSG: 3.65 (+0.32), RNA: 18.65 (unch), PFE: 34.64 (-0.23), SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74)
Cramer's Mad Money: Cramer's Game Plan (1/16/15)
SA Editor Michael Hopkins - at Seeking Alpha - Sun Jan 18, 12:06AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, January 16. After a few big drubbings, stocks caught a break Friday, thanks to a rally in oil and a strong consumer confidence number, data Cramer said is...
GD: 137.61 (-0.54), GE: 25.15 (+0.26), BOX: 20.18 (+0.01), NKE: 92.04 (+0.04), HON: 104.38 (+0.88), DAL: 44.50 (-0.31), RLYP: 33.98 (+0.60), UNH: 109.44 (-0.40), HAL: 44.19 (+1.42), BAC: 16.61 (-0.06), EEP: 38.84 (-0.50), SLB: 88.38 (+2.42), PEP: 99.13 (-1.14), NFLX: 466.10 (+9.37), SBUX: 91.58 (-0.24), UA: 73.76 (-0.19), PBR: 6.98 (+0.44), WBA: 78.73 (-1.23), IBM: 160.40 (+1.88), STI: 41.57 (+0.01), PTCT: 53.37 (-0.74), LEN.B: 40.12 (-0.13), VZ: 49.31 (-0.21), UNP: 122.60 (-1.23), URI: 92.98 (+1.41)
Jim Cramer's Top Stock Picks: GD PTCT RLYP HON PEP
at The Street - Sat Jan 17, 5:00AM CST
Cramer says he'd buy General Dynamics ahead of earnings and he's a big fan of Honeywell and Pepsico.
GD: 137.61 (-0.54), HON: 104.38 (+0.88), RLYP: 33.98 (+0.60), PTCT: 53.37 (-0.74), PEP: 99.13 (-1.14)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Jan 16, 7:33PM CST
Cramer will be watching Europe plue earnings from Halliburton, Starbucks and Verizon, among many others.
GD: 137.61 (-0.54), ZIOP: 9.64 (-0.35), AVP: 9.08 (+0.39), HON: 104.38 (+0.88), UNH: 109.44 (-0.40), RLYP: 33.98 (+0.60), DECK: 77.08 (+0.61), HAL: 44.19 (+1.42), CVRR: 20.20 (+0.58), DENN: 10.68 (+0.03), PEP: 99.13 (-1.14), SBUX: 91.58 (-0.24), NFLX: 466.10 (+9.37), IBN: 11.70 (+0.06), IBM: 160.40 (+1.88), PTCT: 53.37 (-0.74), VZ: 49.31 (-0.21), UNP: 122.60 (-1.23), URI: 92.98 (+1.41)
Sarepta Is Suffering From Overreaction
Value Insight - at Seeking Alpha - Thu Jan 15, 8:00AM CST
SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74)
PTC Therapeutics to Present at the 33rd Annual J.P. Morgan Healthcare Conference
PR Newswire - Wed Jan 07, 7:00AM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the 33rd Annual J.P. Morgan Healthcare Conference on Thursday, January 15th at 11:00 am PT at the Westin St. Francis in San Francisco.
JPM: 59.67 (+0.10), PTCT: 53.37 (-0.74)
Jim Cramer's 'Mad Money' Recap: Knowing Where to Look for Bargains
at The Street - Tue Jan 06, 7:25PM CST
The markets are presenting a buying opportunity at current levels, but only if you know which stocks to buy, Cramer says.
TSLA: 203.77 (+0.89), GE: 25.15 (+0.26), OVAS: 44.32 (+0.87), NMM: 12.37 (+0.24), XOM: 93.37 (+1.00), T: 34.66 (+0.05), ESPR: 67.13 (-0.33), IBM: 160.40 (+1.88), IRE: 14.54 (+0.81), DTV: 87.51 (-0.32), PTCT: 53.37 (-0.74), RCPT: 115.83 (-0.66), TEG: 75.56 (-1.61), PPG: 236.77 (+3.74), WAG: 76.05 (-0.49), BLUE: 90.70 (+0.93), TGTX: 13.13 (-0.19), WFC: 55.33 (+0.47), BA: 149.73 (+1.64), RAD: 8.34 (+0.25), ISIS: 63.86 (-0.43), RNA: 18.65 (unch), ACHN: 10.89 (-0.20), JCP: 8.05 (+0.14), CVS: 102.63 (-0.37), MCD: 95.65 (+0.56), AGIO: 118.55 (+0.11), CVX: 112.78 (+1.92), VZ: 49.31 (-0.21), FOLD: 8.36 (-0.11)
PTC Therapeutics awards inducement grants to 11 new employees under NASDAQ Listing Rule 5635(c)(4)
M2 - Mon Jan 05, 6:05AM CST
Biopharmaceutical company PTC Therapeutics (NasdaqGS
TCT) on Friday authorised non-statutory stock options to purchase an aggregate of 26,600 shares of its common stock to 11 new employees in accordance with NASDAQ Listing Rule 5635(c)(4). PTCT: 53.37 (-0.74)
The Market's Top 10 Stocks of 2014
Dan Caplinger, The Motley Fool - Motley Fool - Sat Jan 03, 8:00AM CST
For six years now, investors have looked with skepticism at the rise in the stock market. And for a sixth straight year, the markets defied those who were waiting for a major downturn to invest, with the S&P 500 climbing about 14% including...
BLUE: 90.70 (+0.93), TTPH: 35.18 (-0.73), AVNR: 16.96 (unch), SWKS: 81.85 (-0.57), CMRX: 40.16 (+0.08), ACHN: 10.89 (-0.20), HA: 18.72 (-0.31), RCPT: 115.83 (-0.66), PTCT: 53.37 (-0.74), AGIO: 118.55 (+0.11)
PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire - Fri Jan 02, 4:15PM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 2, 2015 it approved non-statutory stock options to purchase an aggregate of 26,600 shares of its common stock to 11 new employees. The awards were made pursuant to the NASDAQ inducement grant exception as a component of our new hires' employment compensation.
PTCT: 53.37 (-0.74)
The Zacks Analyst Blog Highlights: Tekmira, Chimerix, Gilead, AbbVie, Achillion Pharmaceuticals, Agios Pharmaceuticals, PTC Therapeutics and Tetraphase Pharmaceuticals
PR Newswire - Mon Dec 29, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Tekmira (Nasdaq:TKMR-Free Report), Chimerix (Nasdaq:CMRX-Free Report), Gilead (Nasdaq:GILD-Free Report), AbbVie (NYSE:ABBV-Free Report), Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN-Free Report), Agios Pharmaceuticals, Inc. (Nasdaq:AGIO-Free Report), PTC Therapeutics, Inc. (Nasdaq
TCT-Free Report) and Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH-Free Report). ACHN: 10.89 (-0.20), PTCT: 53.37 (-0.74), AGIO: 118.55 (+0.11)
PTC Therapeutics Starts Rolling NDA Filing for Translarna - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 3:10PM CST
PTC Therapeutics (PTCT) initiated the process of a rolling submission of a new drug application to the FDA for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy.
RNA: 18.65 (unch), SRPT: 12.76 (+0.11), PTCT: 53.37 (-0.74), BIOD: 1.38 (-0.14)
PTC Therapeutics begins rolling submission of Translarna's NDA to the US FDA for treating nonsense mutation Duchenne muscular dystrophy
M2 - Wed Dec 24, 3:46AM CST
Biopharmaceutical company PTC Therapeutics (NasdaqGS
TCT) reported on Tuesday the initiation of a rolling submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). PTCT: 53.37 (-0.74)
BioMarin CEO Sees Big Future For Prosensa Drug
at Investor's Business Daily - Tue Dec 23, 3:11PM CST
BioMarin Pharmaceuticals raised a few eyebrows last month when it announced its latest buyout. BioMarin (BMRN) agreed to pay $680 million upfront for Prosensa Holding (RNA), a Dutch biotech developing a drug for Duchenne muscular dystrophy called...
BMRN: 100.76 (+1.98), RNA: 18.65 (unch), PTCT: 53.37 (-0.74), GSK: 47.94 (+1.99)
PTC Therapeutics begins rolling NDA for DMD
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:20AM CST
ROSG: 3.65 (+0.32), RNA: 18.65 (unch), SRPT: 12.76 (+0.11), PFE: 34.64 (-0.23), PTCT: 53.37 (-0.74)
PTC Therapeutics Begins Rolling NDA Submission to the FDA for Translarna to Treat Duchenne Muscular Dystrophy
PR Newswire - Tue Dec 23, 7:00AM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has commenced a rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for Translarna(TM) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). A rolling submission allows completed portions of the application to be submitted and reviewed by the FDA on an ongoing basis. PTC expects to finalize the application in the fourth quarter of 2015 following the completion of the ACT DMD confirmatory Phase 3 clinical trial.
PTCT: 53.37 (-0.74)
